McKesson
MCK · NYSE · Healthcare · Pharmaceutical Distribution & Specialty Services
LIVE MARKET DATA NOT YET CONNECTED — price, movement, and market cap will appear here with source and timestamp once a data provider is integrated.
Red Cardinal Snapshot
WHAT IT DOES
McKesson buys pharmaceuticals from manufacturers and delivers them to pharmacies, hospitals, and clinics — the wholesale logistics layer of American medicine. Around that core it has built specialty businesses: an oncology practice network (US Oncology), prior-authorization technology (CoverMyMeds), and third-party logistics services for drugmakers.
HOW IT MAKES MONEY
By charging a sliver on every unit that moves through its warehouses — fees from manufacturers for distribution and services, plus a spread on generics. The margins are measured in fractions of a percent, so the business only works at enormous scale: revenue among the largest of any U.S. company, profit a thin layer on top. The growing profit engine is specialty — high-cost therapies, oncology services, and technology, where the fee per transaction is far richer than moving boxes.
WHY WE TRACK IT
Distribution is the layer of healthcare nobody sees until it fails. Three companies — McKesson, Cencora, and Cardinal Health — move nearly every pharmaceutical in the country, and McKesson is the biggest. In the GLP-1 era, aging-demographics era, and drug-pricing-reform era, every structural shock to American medicine physically passes through its trucks. It is also the best teaching object in the RC 100 for a counterintuitive lesson: why tiny margins can be a moat rather than a weakness.
THE SIMPLE THESIS
Nobody can afford to compete with a business this thin. McKesson's logistics network, DEA-regulated infrastructure, pharmacy relationships, and working-capital scale would cost billions to replicate for a fraction-of-a-percent margin — so no one tries. The tollbooth is safe; the thesis is whether the climb from commodity distribution into specialty oncology, technology, and biopharma services re-rates the profit pool before disintermediation experiments and pricing reform erode the base.
PREMIUM RESEARCH
The rest of the McKesson dossier
The Five Minute Brief, our intelligence rating and thesis health, the competitive position, the bull and bear cases, what would invalidate the thesis, and every source behind it.
- Five Minute Brief
- Intelligence rating and thesis health
- Competitive position and moat analysis
- Bull case, bear case, and what breaks it
- Systemic importance and cascade effects
- Full source list and methodology
Subscribe to the newsletter and choose 3 dossiers to read in full — this one included, if you like.
Free, and you pick the companies. No card required.